An interventional study of eTSF and Educational materials in Alcohol Use Disorder (AUD), sponsored by University of Texas at Austin. Not yet recruiting. Open to participants aged 18 Years to 29 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University of Texas at Austin · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if the eTSF intervention is feasible among Latinx young adults with alcohol use disorder. The main questions it aims to answer are:
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
This study's planned enrollment of 40 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Browse Alcoholism studies →University of Texas at Austin is the lead sponsor of 328 studies on the registry; 79 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will receive the eTSF intervention. eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.
Behavioral: eTSF
This arm will receive educational materials on drinking problems and a list of local/online AA meetings
Behavioral: Educational materials
eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.
Educational materials on drinking problems and a list of local/online AA meetings.
Recruitment feasibility
Recruitment feasibility will be measured by the number of participants screened and enrolled each month.
Time frame: Every 4 weeks up to 2 years
Randomization feasibility
Randomization feasibility will be measured by the number of baseline demographic variables with statistically significant group differences.
Time frame: From recruitment to baseline assessment up to two years
Retention/attrition feasibility
Retention/attrition feasibility will be measured by retention rates in each condition.
Time frame: From recruitment to the end of the trial at three months.
Adherence feasibility
Adherence feasibility will be measured by the percentage of eTSF app components used by the eTSF condition participants.
Time frame: From recruitment to the end of the trial at three months.
Assessment feasibility
Assessment feasibility will be measured by the proportion of missing data in each assessment.
Time frame: From recruitment to the end of the trial at three months.
Intervention credibility
Intervention credibility will be measured using a single-item question: "On a scale from 1 to 5, where 1 indicates 'not at all' and 5 indicates 'very much,' to what extent do you believe this treatment will be beneficial for you?" Only eTSF condition participants will receive this measure.
Time frame: From baseline to the end of treatment at three months.
Intervention satisfaction
Intervention satisfaction will be measured using the mHealth Satisfaction Questionnaire, which has a total score range from 14 to 42. Higher total scores indicate greater user satisfaction with the mHealth app.
Time frame: From baseline to the end of treatment at three months.
Intervention acceptability
Acceptability will be measured using the Abbreviated Acceptability Rating Profile, which scores range from 8 to 48. Higher scores indicate greater acceptability of the intervention.
Time frame: From baseline to the end of treatment at three months.
Intervention engagement
Intervention engagement will be automatically recorded by the app during the study period and be measured in terms of app opening frequency, time spent on the app per use session (i.e., the time between opening and closing the app), most frequently used intervention component, time spent per intervention component, the completion rate of each selected component, reports of technical problems.
Time frame: From baseline to the end of treatment at three months.
Alcohol use
Alcohol use will be measured using the Time-Line Follow-Back (TLFB) method-Form 90, which helps participants recall and mark days on which they used alcohol during the past 90 days.
Time frame: From baseline to the end of treatment at three months.
12-Step fellowship engagement
12-Step fellowship engagement will be measured with the Multi-Dimensional Mutual-help Activity Scale (MDMAS), which measures seven dimensions of experience (meeting attendance, meeting participation, fellowship involvement, step work, mandated attendance, affiliation, and safety). Total score ranges from 32-160 with higher scores within indicating greater engagement.
Time frame: From baseline to the end of treatment at three months.
Drinking consequences
Drinking consequences will be measured with the Short Inventory of Problems (SIP-2R). Score ranges from 0-45 with higher scores indicating a greater frequency of experiencing problems related to substance use.
Time frame: From baseline to the end of treatment at three months.
Drug use
Drug use will be measured with the aforementioned TLFB-Form 90
Time frame: From baseline to the end of treatment at three months.
Psychological distress
Psychological distress will be assessed with the 18-item Brief Symptom Inventory. Score ranges 0-72 and higher scores indicate greater levels of psychological distress.
Time frame: From baseline to the end of treatment at three months.
No study locations are listed for this record.
Plan to share: Yes — The IPD will be shared on the NIAAA Data Archive.
No publications or documents are linked to this record.
Start is estimated for May 2027; primary completion for Aug 2028, 15 months later.
Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 15 months is below that.
Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.
Start moved twice since we started tracking on Sep 25, 2026: Jan 2027 → May 2027, last on Nov 4, 2026.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2028 → Aug 2028, on Oct 13, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Feb 2029 → Aug 2029, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas at Austin →